Next Investors logo grey

Listed Canadian company delivers 475% more CBD to the bloodstream

Published 17-MAY-2019 14:10 P.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

If Kim Kardashian is spruiking the benefits of cannabinoids (CBD), you know its influence is growing.

Kim Kardashian’s CBD Baby Shower featured a number of Wildflower Brands Inc. (CSE: SUN, OTC: WLDFF) CBD+ wellness products.

The baby shower was a curated CBD themed party designed to provide guests a soothing, relaxing holistic health experience.

“I am freaking out so much, I just want a Zen-like CBD-themed baby shower,” Kardashian told E! News when asked about the theme for the party.

Kardashian’s CBD-based baby shower experience was curated by HelloMD to create an experiential CBD wellness event including a selection of Wildflower products. A variety of treatments featured at the baby shower included a Wildflower CBD+ Pure tincture infused tea station; Wildflower CBD+ Pure tincture infused beverages at the bar; enjoyment of Wildflower’s CBD+ Aches blend Vaporizer before a sound bath; and a CBD bar where guests made their own infused oils and bath salts.

Celebrity baby shower aside, there are various listed companies making big moves in the cannabis wellness space.

A supreme acquisition

The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) and Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B:GR) announced that they have entered into a definitive arrangement agreement that will see Supreme Cannabis acquire all of the issued and outstanding common shares of Blissco not already owned by Supreme Cannabis.

The Arrangement is an all-stock transaction with a total value of approximately C$48 million (AU$51.7).

"Supreme Cannabis is the best positioned company in the cannabis space to help Blissco achieve its ambition of delivering innovative, quality assured full-spectrum cannabis products to the world," said Damian Kettlewell, CEO of Blissco.

"By merging with Supreme Cannabis, Blissco shareholders will benefit from the combined expertise of both companies in growing premium cannabis brands, producing and procuring high-quality inputs, commercializing new products, and ensuring regulatory compliance. Blissco shareholders will also benefit from Supreme Cannabis' enhanced trading liquidity on the TSX and greater access to capital that will allow us to focus and accelerate Blissco's premium wellness business."

"Blissco has built a distinct and authentic premium wellness brand. Through our strategic partnership and prior investment in the company, we developed a deep understanding of the business and a high level of confidence in the senior management team. This transaction will allow Blissco to focus its business around the production and commercialization of cannabis oils and topicals for the premium wellness consumer," said Navdeep Dhaliwal, CEO of Supreme Cannabis.”

More CBD to the bloodstream

Perhaps the biggest news this week features Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), a company which has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules.

Lexaria has proven in animal testing that Lexaria's DehydraTECHTM technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry cannabinoid edible formulation designs that often combine cannabinoids with MCT oils such as coconut oil, a commonly used medium chain triglyceride (MCT) oil in the cannabis edibles industry.

On March 20, 2019, Lexaria announced it had commenced a series of animal studies with multiple objectives, including gaining a better understanding of how edible forms of cannabinoids enter the bloodstream.

Here is an in-depth examination of the testing.

MCT oils are commonly used by many firms making and selling cannabis edibles throughout North America.

Lexaria has consistently said that the use of MCT oil in edibles is less effective for purposes of cannabinoid delivery optimization than its patented DehydraTECH LCFA formulations. Although these studies tested only for CBD delivery, Lexaria believes that virtually identical results would have been achieved if THC was instead the cannabinoid under examination, consistent with subjective human clinical studies Lexaria's partners have conducted with edible THC products.

The cannabis edibles industry has partially embraced the use of MCT oils such as coconut oils as a co-ingredient in edible products, mostly because of the luxurious taste and mouth-feel of coconut oil. Lexaria's head-to-head animal absorption study has proven that coconut oil formulations deliver cannabinoids into animal bloodstreams very poorly at only about one-quarter the rate of the patented Lexaria LCFA formulation. Lexaria's DehydraTECH technology was also shown to deliver CBD considerably more quickly than MCT oil formulations.

The final word

While the Kardashians are playing their role in normalising CBD use, celebrity endorsement is just one facet of what is significant activity in this growing sector.

The science is expanding. And with that, we should see some exciting developments in the industry in the back half of 2019.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.